Personalized radioiodine therapy for thyroid cancer patients with known disease.
Sissy M JhiangPeng ChengFadi A NabhanJennifer A SiposChia-Hsiang MenqPublished in: Faculty reviews (2021)
Radioactive iodine (RAI) 131I is a targeted therapy for patients with RAI-avid follicular cell-derived thyroid cancer. However, the responsiveness to 131I therapy varies among thyroid cancer patients mainly owing to differential RAI uptake and RAI radiosensitivity among patients' lesions. A personalized approach to maximize 131I therapeutic efficacy is proposed based on recent scientific advances and future opportunities.